arrow
F

Francesco Forconi

University of Southampton
H指数:59
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study

阿卡巴鲁替尼单药治疗作为CLL的一线治疗:真实世界EPIC研究的3年随访

2026-05-020
OAAI
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

奥加曲沙在瓦尔登斯特伦巨球蛋白血症中,5年随访显示持久应答

2026-04-170
OAAI
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis

CD40L和IL-4通过hla-e: NKG2A轴抑制NK细胞介导的抗体依赖性细胞毒性

2025-01-010
OA
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
LEUKEMIA
IF13.4
2024-06-084
OAAI
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

以可测量的残留疾病为指导的慢性淋巴细胞白血病治疗

2024-01-2550
OA
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

BTK和PLCG2在接受依鲁替尼治疗的CLL复发患者的3分之1中保持未突变

2023-06-1638
OAAI
Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL

网络分析揭示了14q32簇mirna在确定IGHV突变和未突变CLL之间的转录差异中的主要作用

LEUKEMIA
IF13.4
2023-05-111
OAAI
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
2022-12-1313
OAAI
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

在FCR治疗的慢性淋巴细胞白血病的真实多中心队列中,IGHV突变患者的长期益处

2022-10-103
PRE
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

高表面IgM水平与CLL患者对ibrutinib和BTK旁路的较短反应相关

2022-09-266
OAAI
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
2022-06-285
OAAI